Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420952 · ClinicalTrials.gov registry record · Phase 1
Imaging of Brain Receptors Using (11C)mGlu1
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01420952 is a Phase 1 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 3 participants.
The verdict
NCT01420952, a Phase 1 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to better understand how they are involved in general health, brain disorders, and addiction. Objectives: * To test how (11C)mGlu1 is distributed in the brain and body. * To measure how mGluR1 receptors display (11C)mGlu1 during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. This study requires four visits to the NIH Clinical Center. * Participants will have an initial evaluation, a magnetic resonance imaging (MRI) scan, a PET scan, and a final blood sample after the PET scan, all at different visits. * The MRI and PET scans will focus on the brain. Participants will receive (11C)mGlu1, and have scans to see how it shows up in the brain. * Some participants will have whole body imaging studies to see how (11C)mGlu1 shows up in the body.
Interventions
- DRUG [11C]LY2428703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-07-29 |
| Est. Completion | 2012-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420952
The ClinicalTrials.gov registry entry for NCT01420952 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]LY2428703 is the first listed.
NCT01420952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01420952 about?
NCT01420952 is a clinical study titled "Imaging of Brain Receptors Using (11C)mGlu1". Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to...
What is the current status of trial NCT01420952?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-07-29. Estimated completion is 2012-11-27.
What interventions are being tested in trial NCT01420952?
The interventions under investigation include: [11C]LY2428703 (DRUG).
Who is sponsoring clinical trial NCT01420952?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.